Chiba, Japan

Toshinori Ozaki



Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2009-2011

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Toshinori Ozaki: Innovator in Neurodegenerative Disease Research

Introduction

Toshinori Ozaki is a prominent inventor based in Chiba, Japan. He has made significant contributions to the field of neurodegenerative diseases through his innovative research and patented methods. With a total of 3 patents, his work focuses on understanding and treating conditions such as Alzheimer's disease.

Latest Patents

Ozaki's latest patents include a method for screening apoptosis-accelerating compounds or anti-apoptotic compounds. This method involves measuring the interaction between p53 and NEDL1 in the presence and absence of a test compound, allowing researchers to compare the strength of this interaction. Additionally, he has developed a screening method for identifying drugs aimed at preventing and treating Alzheimer's disease. This invention is based on a novel mechanism of Alzheimer's onset, distinct from the traditional amyloid hypothesis.

Career Highlights

Throughout his career, Toshinori Ozaki has worked with notable organizations, including Hisamitsu Pharmaceutical Company, Inc. and the Chiba-prefecture. His expertise in the field has led to advancements in the understanding of neurodegenerative diseases and potential therapeutic approaches.

Collaborations

Ozaki has collaborated with various professionals in his field, including his coworker Akira Nakagawara. These partnerships have contributed to the development of innovative solutions for complex medical challenges.

Conclusion

Toshinori Ozaki's contributions to neurodegenerative disease research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for new treatments and a deeper understanding of these conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…